Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

Bristol-Myers Squibb could be on the verge of a major coup in psoriasis after its deucravacitinib pill outperformed Amgen’s rival Otezla. BMS had to sell off Otezla (apremilast) as a condition ...

Bristol-Myers Squibb's hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure in ulcerative ...

Deucravacitinib, an oral allosteric TYK2 inhibitor recently approved by the FDA for treating moderate-to-severe psoriasis, has set the clinical precedent for selectively targeting TYK2 activity in ...

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates ...